Cantor Fitzgerald restated their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a report published on Friday. They currently have a $135.00 price objective on the biopharmaceutical company’s stock.
“. We reiterate our Overweight rating and 12-mo. $135 PT. Alnylam hosted an R&D day Thursday, where pipeline updates and long-term strategy were largely in line with our recently published expectations here. With three Ph3 readouts and two potential NDA filings in 2019 alone, we think ALNY is well on its way to establishing itself as a diversified global commercial biotech company, if pipeline execution continues. We see many late and mid-stage readouts over the next 12 months that will help ALNY build more commercial and mid/late- stage products (see p. 2). ALNY will preannounce 4Q18 Onpattro sales in early Jan. 2019.”,” Cantor Fitzgerald’s analyst commented.
ALNY has been the subject of several other reports. Cowen reiterated a buy rating and issued a $147.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, September 4th. JMP Securities set a $198.00 target price on Alnylam Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, August 28th. Needham & Company LLC set a $152.00 target price on Alnylam Pharmaceuticals and gave the stock a buy rating in a report on Monday, August 27th. ValuEngine upgraded Alnylam Pharmaceuticals from a buy rating to a strong-buy rating in a report on Tuesday, August 28th. Finally, BidaskClub upgraded Alnylam Pharmaceuticals from a sell rating to a hold rating in a report on Thursday, August 23rd. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and thirteen have issued a buy rating to the company. The company has an average rating of Buy and an average target price of $138.44.
Shares of ALNY traded down $5.35 on Friday, reaching $74.38. 1,099,741 shares of the company’s stock were exchanged, compared to its average volume of 737,079. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.05 and a quick ratio of 10.96. The company has a market cap of $8.06 billion, a price-to-earnings ratio of -13.72 and a beta of 2.54. Alnylam Pharmaceuticals has a 12 month low of $63.57 and a 12 month high of $153.99.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($2.43) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.02) by ($0.41). The business had revenue of $2.07 million for the quarter, compared to the consensus estimate of $22.66 million. Alnylam Pharmaceuticals had a negative return on equity of 43.07% and a negative net margin of 754.13%. The company’s quarterly revenue was down 87.9% on a year-over-year basis. During the same period last year, the firm earned ($1.34) earnings per share. As a group, analysts expect that Alnylam Pharmaceuticals will post -7.75 EPS for the current year.
A number of large investors have recently made changes to their positions in ALNY. Tower Research Capital LLC TRC increased its position in Alnylam Pharmaceuticals by 768.5% during the 3rd quarter. Tower Research Capital LLC TRC now owns 1,294 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 1,145 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC acquired a new position in shares of Alnylam Pharmaceuticals in the second quarter valued at about $137,000. Opera Trading Capital acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at about $137,000. Mutual of America Capital Management LLC increased its holdings in shares of Alnylam Pharmaceuticals by 98.5% in the second quarter. Mutual of America Capital Management LLC now owns 1,935 shares of the biopharmaceutical company’s stock valued at $191,000 after purchasing an additional 960 shares during the period. Finally, Harel Insurance Investments & Financial Services Ltd. increased its holdings in shares of Alnylam Pharmaceuticals by 600.9% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,278 shares of the biopharmaceutical company’s stock valued at $200,000 after purchasing an additional 1,953 shares during the period. 88.46% of the stock is currently owned by institutional investors.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
Featured Story: How can you know how many shares are floating?
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.